drugset / Trial / NCT00697593

ChangE From Any Systemic psoriasiS therapY to Raptiva

NCT00697593

Phase 4 Terminated 70 enrolled Merck KGaA, Darmstadt, Germany
NaSingle-groupOpen-labelTreatment

Summary

To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.

Timeline

Start
2008-01
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject efalizumab Monoclonal antibody 1 mg/kg

Indications